Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
 | |
Valeant Pharmaceuticals International. (PRNewsFoto/Valeant Pharmaceuticals International)
ALISO VIEJO, CA UNITED STATES
|
| |
ALISO VIEJO, Calif., March 19 /PRNewswire-FirstCall/ -- Valeant
Pharmaceuticals (NYSE: VRX) today announced that it has appointed Dr.
Bhaskar Chaudhuri to the position of President, Valeant Pharmaceuticals
International, effective March 10, 2009. In this role, Dr. Chaudhuri will
assume responsibility for overseeing the Dow Services business, corporate
business development activities, the branded generics operations in Mexico
and Poland, and will be a member of Valeant's Executive Management Team.
About Dr. Bhaskar Chaudhuri
Prior to joining Valeant upon the Company's acquisition of Dow
Pharmaceutical Sciences, Inc. on December 31, 2008, Dr. Chaudhuri served
for seven years as President and Chief Executive Officer and a Member of
Dow's Board of Directors. Before joining Dow, Dr. Chaudhuri served as
Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, a
subsidiary of Mylan Laboratories, where he oversaw the research and
development activities for its Cardiovascular, Neurology and Dermatology
businesses, as well as a segment of its manufacturing operations.
Prior to his positions at Bertek, Dr. Chaudhuri served as the General
Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri
joined Mylan through the acquisition of Penederm Inc., where he was the
Vice President of R&D from 1992 to 1998.
Dr. Chaudhuri has over 20 years experience in pharmaceutical management
service, research and development. He holds a Doctorate in Physical
Pharmacy, a Masters of Science in Industrial Pharmacy and a Bachelors of
Science in Pharmacy.
As is the case with other members of Valeant's senior management, Dr.
Chaudhuri's compensation package is directly linked to the performance of
Valeant and is intended to provide a strong and direct link to the
company's future.
About Valeant
Valeant Pharmaceuticals International (NYSE: VRX) is a multinational
specialty pharmaceutical company that develops, manufactures and markets a
broad range of pharmaceutical products primarily in the areas of neurology
and dermatology. More information about Valeant can be found at
http://www.valeant.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, including, but
not limited to, statements regarding the future of Valeant's business and
performance. These statements are based upon the current expectations and
beliefs of Valeant's management and are subject to certain risks and
uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. These risks and
uncertainties include, but are not limited to, risks and uncertainties
related to Valeant's ability to successfully integrate its acquisitions and
to realize the benefits of these acquisitions and management's ability to
improve operations, as well as other risks and uncertainties discussed in
the company's filings with the SEC. The company cautions the reader that
these factors are among the factors that could cause actual results to
differ materially from the expectations described in the forward-looking
statements. The company also cautions the reader that undue reliance should
not be placed on any of the forward-looking statements, which speak only as
of the date of this press release. The company undertakes no responsibility
to update any of these forward-looking statements to reflect events or
circumstances after the date of this press release or to reflect actual
outcomes.
Contact:
Laurie W. Little
Valeant Pharmaceuticals
949-461-6002
(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)
